New immunotherapy combo for advanced liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of two immunotherapy drugs, cadonilimab and AK112, as a second option for people with advanced liver cancer who have already tried standard first-line treatment and it stopped working or caused too many side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of liver cancer (hepatocellular carcinoma).
- You are between 18 and 75 years old.
- You have already received a first treatment that included immunotherapy and an anti-angiogenesis drug, but your cancer got worse or you couldn't tolerate the side effects.
- You have at least one tumor that can be measured on a scan.
- You are able to take care of yourself (ECOG score 0 or 1) and your liver function is fairly good (Child-Pugh A or B7).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug called AK112 for people with advanced liver cancer that hasn't spread to the brain or key blood vessels. It may be an option if you haven't had immunotherapy before and your liver is still working well.
This trial tests a new combination therapy (AK104 plus lenvatinib) compared to lenvatinib alone for people with advanced liver cancer that has progressed after first-line treatment with atezolizumab and bevacizumab. The goal is to see if the combination can help control the cancer better.
This trial tests a new medicine, PF-08634404, alone or with other treatments for adults with advanced liver cancer that cannot be removed by surgery or has spread. It is for people who have not had prior systemic therapy and have good liver function.
This trial tests a combination of immunotherapy (anti-PD-1/PD-L1) and an anti-VEGF drug for people with advanced hepatocellular carcinoma (HCC), a type of liver cancer that cannot be removed by surgery or has spread. The goal is to see if these drugs can shrink tumors or slow the cancer's growth.
This trial tests a combination of two treatments for advanced liver cancer: TACE (a procedure that blocks the blood supply to the tumor) and an anti-PD-1 antibody (a type of immunotherapy that helps your immune system fight cancer). The goal is to see if this combination works better than either treatment alone and to understand how it affects the immune system around the tumor.
This trial tests if adding a new combination of drugs (AK104 and lenvatinib) to a standard liver cancer procedure called TACE is more effective than TACE alone. It is for people whose liver cancer has not spread and cannot be removed by surgery, but who are well enough to receive these treatments.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.